Impact of GeneXpert MTB/RIF Assay for the Detection of Pulmonary and Extrapulmonary Tuberculosis from Clinical Samples

Research Article

Austin J Public Health Epidemiol. 2025; 12(1): 1173.

Impact of GeneXpert MTB/RIF Assay for the Detection of Pulmonary and Extrapulmonary Tuberculosis from Clinical Samples

Pradhabane G1, Muthukumar A2, Blasundaram RM3, Prakash V4, Vadakunnel MJ4, Ramachandra V4, Palavesam S4, Subaramani S5 Muthaiah M5*, Soundappan G5 and Fredrick A6

1Department of Biotechnology, Indira Gandhi College of Arts and Science, Indira Nagar, Puducherry, India

2Department of Environmental Science, Central University, Kasaragod, Kerala, India

3Department of Biochemistry, Queen Mary’s College, Madras, Tamil Nadu, India

4Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu, India

5Department of Microbiology, State TB Training and Demonstration Centre, Intermediate Reference Laboratory, Government Hospital for Chest Diseases, Puducherry, India

6State TB Control Office, Chennai, Tamil Nadu, India

*Corresponding author: Dr. Muthuraj Muthaiah, Department of Microbiology, State TB Training and Demonstration Centre, Intermediate Reference Laboratory, Government Hospital for Chest Diseases, Puducherry, India Email: drmuthurajm@gmail.com

Received: January 06, 2025; Accepted: January 28, 2025; Published: January 31, 2025

Abstract

Background: Tuberculosis (TB) is a remains major infectious disease, particularly in developing countries. Diagnosing TB remains challenging, and the rise of drug-resistant strains poses a serious risk in resource-limited settings. Therefore, improving TB diagnosis is a global priority for effective control. This study aimed to evaluate the diagnostic accuracy of the GeneXpert MTB/RIF assay for identifying both pulmonary TB and extrapulmonary TB. Additionally, it assessed the performance of the GeneXpert system in detecting rifampicin resistance among the patients involved.

Methods: Clinical samples were collected from patients undergoing clinical and radiological evaluations for either Pulmonary Tuberculosis or Extrapulmonary Tuberculosis. These samples were processed and tested for Mycobacterium tuberculosis presence using the GeneXpert assay.

Results: Its sensitivity is 99.8% for pulmonary tuberculosis, and specificity is 99.9% for extrapulmonary tuberculosis. Among the 15.01% of individuals suspected of having tuberculosis, the positivity rates vary by group: 7.54% in people living with HIV (PLHIV), 2.22% in paediatric patients, 20.53% in smearnegative cases, 14.45% in individuals with X-ray results suggestive of TB, and 16.97% in vulnerable groups according to Active Case Finding guidelines. Furthermore, 9.78% of contacts of TB and drug-resistant TB patients tested positive, along with 14.88% in EPTB cases. Contacts of TB and Drug-resistant TB patients have an increased risk, with 23.76% diagnosed with rifampicinresistant tuberculosis. Patients who had contact with TB or DRTB patients have 7.87 times the odds of developing rifampicin-monoresistant TB compared to those without such contacts.

Conclusion: The GeneXpert MTB/RIF assay is a rapid and highly sensitive method for diagnosing PTB and EPTB. Its simplicity and accuracy make it an impressive and valuable tool for detecting M.tuberculosis and rifampicin resistance.

Keywords: Mycobacterium tuberculosis; GeneXpert; Rifampicin resistant; Sensitivity; Specificity; Positive Predictive Value; Negative Predicative Value

Abbreviations

RR-TB: Rifampicin-resistant Tuberculosis; PBS: Phosphate- Buffered Saline; DR-TB: Drug-Resistant Tuberculosis; DS-TB: Drug- Sensitive Tuberculosis; MDR TB: Multidrug-Resistant Tuberculosis; TB: Tuberculosis; MTB: Mycobacterium Tuberculosis; NTM: Non- Tuberculous Mycobacteria; EPTB: Extrapulmonary Tuberculosis; PTB: Pulmonary Tuberculosis; CI: Confidence Interval; HIV: Human Immunodeficiency Virus; WHO: World Health Organization; PMDT: Programmatic Management of Drug-Resistant Tuberculosis; NAAT: Nucleic Acid Amplification Test; CSF: Cerebrospinal Fluid; OR: Odds Ratio

Introduction

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is one of the leading causes of mortality worldwide and ranks among the deadliest infectious diseases. Despite extensive global efforts, TB continues to be a significant public health threat, particularly in developing and underdeveloped countries. The World Health Organization (WHO) estimates that in 2023, approximately 10.8 million people were infected with TB, consisting of 55% men, 33% women and 12% children and young adolescents. That year, TB resulted in an estimated 1.25 million deaths, including 161,000 individuals living with HIV. Eight countries accounted for more than two-thirds of the global total of TB cases: India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh, and the Democratic Republic of the Congo. Notably, the top five countries together accounted for 56% of the global TB burden [1]. Diagnosing tuberculosis (TB) can be difficult due to its nonspecific symptoms and the paucibacillary nature of the disease. Accurately detecting M.tuberculosis is essential for diagnosing TB, which primarily affects the lungs and is transmitted through respiratory means. The GeneXpert MTB/RIF assay (Xpert) is a diagnostic tool that has significantly improved the accuracy of TB detection in clinical settings, offering enhanced sensitivity and specificity [2]. While early detection of TB can be challenging, Xpert has increased the effectiveness of the diagnostic process. However, the accuracy of Xpert can vary based on different diagnostic specimens and the sites of TB infection. Therefore, selecting the appropriate specimens is crucial when using Xpert to identify suspected TB cases. This study assesses the effectiveness of Xpert in diagnosing various types of TB using different specimens.

Methods

Study Settings

Early morning sputum samples (2-4 ml) were collected in presterilized 50 ml Falcon tubes and processed at ten NAAT (Nucleic Acid Amplification Test) sites from January to December 2023 using GeneXpert for M.tuberculosis and Rifampicin-resistance detection. Extra pulmonary samples were processed at the Intermediate Reference Laboratory with GeneXpert instruments. In this study, we successfully enrolled a total of 37695 tuberculosis (TB) suspects from Puducherry, contributing 9,554 participants. Additionally, we collected data from nine neighboring districts in Tamil Nadu, which included Villupuram (2,837 participants), Kallakuruchi (3,243), Cuddalore (2,412), Tiruchirappalli (7,592), Perambalur (2,164), Thiruvarur (3,721), Nagapattinam (1,021), Thanjavur (2,077), and Tiruvannamalai (3,074). This comprehensive enrolment highlights our significant effort to address TB suspicion in the region.

Sputum Sample Processing for GeneXpert MTB/RIF Assay

The GeneXpert sample reagent was added to each sputum specimen at a 2:1 (v/v) ratio using a sterile pipette. The sputum cup was shaken vigorously 10 to 20 times and then incubated at room temperature for 15 minutes, with at least one shake during incubation. Afterward, the sample should be liquefied without clumps. Each GeneXpert MTB/RIF cartridge was labelled with the lab accession number, either by writing on the cartridge or using the provided transfer pipette. The liquefied sample was drawn into the pipette and transferred into the cartridge. It’s crucial to ensure the lab numbers match. After labelling, the pre-printed barcode on the cartridges was scanned, and the cartridge was loaded into the GeneXpert instrument. A green light indicates the test has started, and the results print automatically when complete. Wait for the system to release the door before removing the cartridge, and dispose of used cartridges in a biohazard waste container [3-4].

Tissues Sample Processing for GeneXpert MTB/RIF Assay

Lymph nodes and tissue samples were cut into small pieces with sterile tools and placed in a sterile mortar. Approximately 2 mL of sterile phosphate-buffered saline (PBS) was added, and the mixture was ground into a homogeneous suspension. Next, 0.7 mL of this homogenized sample was transferred to a sterile tube, followed by the addition of 1.4 mL of GeneXpert MTB/RIF Sample Reagent. The mixture was shaken vigorously for at least 10 seconds and incubated at room temperature for 10 minutes, with additional shaking. After incubation, 2 mL of the processed sample was transferred to a GeneXpert MTB/RIF cartridge, ensuring the correct laboratory number was recorded. The barcode was scanned, and the cartridge was loaded into the GeneXpert instrument. Testing initiated when the green light stopped blinking, and results were printed automatically. The cartridge was removed only after the system unlocked the door, and used cartridges were disposed of in a biohazard container [5].

CSF Samples Processing for GeneXpert MTB/RIF Assay

If the cerebrospinal fluid (CSF) sample is less than 2 mL, add an equal volume of GeneXpert MTB/RIF sample reagent and transfer about 2 mL of the mixture into the GeneXpert cartridge. Load it into the instrument as per the manufacturer’s instructions. For samples over 2 mL, transfer the entire volume to a sterile conical tube and centrifuge for 15 minutes at 4000 rpm. Discard the supernatant in a suitable disinfectant. Add 2 mL of GeneXpert reagent to the deposit and transfer 2 mL to the cartridge. Ensure the laboratory number matches the cartridge and sputum cup. Switch on the GeneXpert, scan the pre-labelled barcode, and load the cartridge. Start the test by clicking the appropriate button—when the green light stops blinking, the test has begun. Wait for the green light to turn off at the end of the test, then remove the cartridge and dispose of it in the biohazard container [3].

Ethical Consideration

The study was approved by the Ethics and Scientific Review Committee at the General Hospital Institute, Puducherry, and conducted according to WHO guidelines and the National Tuberculosis Elimination Program.

Statistical Analysis

Logistic regression analysis was used to evaluate the odds ratio for multidrug-resistant/rifampicin-resistant tuberculosis, utilizing MedCalc software (version 22.026) [6].

Results

Of 37695 samples, 28141 were collected from nine adjoining districts of Tamil Nadu, while 9,554 samples came from Puducherry state. Among the 37695 samples, 74.45% (29114) were classified as pulmonary cases, and 21.94% (8,581) were categorized as extrapulmonary cases. Additionally, 87.08% of the samples were considered presumptive TB, whereas 12.92% were deemed presumptive DR-TB. Furthermore, of the 37695 samples, 92.36% (34814) were received from the public sector, and 7.64% (2,881) were obtained from the private sector, as illustrated in Figure 1. Of 29114 pulmonary samples, 21.42% (6,236) were positive for tuberculosis, and 1.65% (479) were rifampicin-resistant. Among 8,581 extrapulmonary samples, 10.72% (920) were positive for tuberculosis, and 0.35% were rifampicin-resistant, as shown in Figure 2. Out of 32825 presumptive patient samples, 15.01% (4927) tested positive for tuberculosis, with 0.63% (208) being rifampicin-resistant. Among 4870 presumptive DR-TB patient samples, 45.77% (2229) tested positive for tuberculosis, and 6.18% were rifampicin-resistant, as shown in Figure 3.